Forodesine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Forodesine" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

2shareholder.com

6,233^rd place

5,563^rd place

18^th place

17^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

"Complete list of clinical trials for forodesine (BCX-1777) (ClinicalTrials.gov)". Retrieved 2008-07-22.

doi.org (Global: 2^nd place; English: 2^nd place)

Kicska GA, Long L, Hörig H, Fairchild C, Tyler PC, Furneaux RH, et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 98 (8): 4593–4598. Bibcode:2001PNAS...98.4593K. doi:10.1073/pnas.071050798. PMC 31879. PMID 11287638.
Makita S, Maeshima AM, Maruyama D, Izutsu K, Tobinai K (2018). "Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review". OncoTargets and Therapy. 11: 2287–2293. doi:10.2147/OTT.S140756. PMC 5916385. PMID 29719411.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Kicska GA, Long L, Hörig H, Fairchild C, Tyler PC, Furneaux RH, et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 98 (8): 4593–4598. Bibcode:2001PNAS...98.4593K. doi:10.1073/pnas.071050798. PMC 31879. PMID 11287638.

nih.gov (Global: 4^th place; English: 4^th place)

ncbi.nlm.nih.gov

Kicska GA, Long L, Hörig H, Fairchild C, Tyler PC, Furneaux RH, et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 98 (8): 4593–4598. Bibcode:2001PNAS...98.4593K. doi:10.1073/pnas.071050798. PMC 31879. PMID 11287638.
Makita S, Maeshima AM, Maruyama D, Izutsu K, Tobinai K (2018). "Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review". OncoTargets and Therapy. 11: 2287–2293. doi:10.2147/OTT.S140756. PMC 5916385. PMID 29719411.

pubmed.ncbi.nlm.nih.gov

Kicska GA, Long L, Hörig H, Fairchild C, Tyler PC, Furneaux RH, et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 98 (8): 4593–4598. Bibcode:2001PNAS...98.4593K. doi:10.1073/pnas.071050798. PMC 31879. PMID 11287638.
Makita S, Maeshima AM, Maruyama D, Izutsu K, Tobinai K (2018). "Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review". OncoTargets and Therapy. 11: 2287–2293. doi:10.2147/OTT.S140756. PMC 5916385. PMID 29719411.

shareholder.com (Global: 6,233^rd place; English: 5,563^rd place)

investor.shareholder.com

"Biocryst Initiates Pivotal Fodosine Phase IIb Clinical Trial In Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma" (Press release). January 16, 2007.
"BioCryst Announces Mundipharma Receives Approval for Mundesine in Japan" (Press release). April 3, 2017.